News

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat moderate-to-severe obstructive sleep apnea in adults with obesity.

From a changing consumer, to an unsteady regulatory environment and the entry of a heavy hitter, e-commerce has had to adapt to stay agile.

Major U.S. indexes were mixed at midday Monday to start the holiday-shortened trading week.

Stock market pros expect more muted gains in 2025 compared to the past few years.

Veteran trader Stephen 'Sarge' Guilfoyle is placing his bets on a familiar technology name in 2025.

LMT's 320-day moving average has acted as a springboard in the past

RAPT Therapeutics, Inc. (NASDAQ:RAPT) shares are trading higher after the company disclosed a partnership with Shanghai Jemincare Pharmaceutical. The collaboration is for an exclusive license agreement to develop and commercialize RPT904, a novel anti-IgE monoclonal antibody worldwide, excluding mainland China, Hong Kong, Macau, and Taiwan. RPT904 is designed to provide a potential alternative to omalizumab (Xolair), addressing allergic conditions such as asthma and chronic spontaneous urticaria